FDA Adds Fasenra Indication for Severe Asthma in Children

TUESDAY, April 16, 2024-- The U.S. Food and Drug Administration has approved an additional indication for Fasenra (benralizumab) as an add-on maintenance treatment for patients aged 6 to 11 years with severe asthma and an eosinophilic...